JAMA Network
About The Study: This randomized clinical trial found that treatment with abatacept, cenicriviroc, or infliximab showed no significant difference of time to recovery compared with placebo for patients hospitalized with COVID-19 pneumonia.
Authors: William G. Powderly, M.D., of the Washington University School of Medicine in St. Louis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.11043)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
